Quick Facts: Main Therapeutic Uses

• May help reduce the chance of pregnancy after unprotected sexual intercourse.
• Used as a backup method of contraception following known or suspected contraceptive failure.
• Is a form of emergency contraception and is not intended for routine, ongoing use.

---

Levonorgestrel is used to assist in the prevention of pregnancy following unprotected sexual intercourse or when a regular method of birth control is known or suspected to have failed. This medication is a form of emergency contraception and serves as a backup option to routine contraception. It is generally understood to act by affecting the process of ovulation, which is the release of an egg from the ovary.

To achieve the intended effect, the treatment should be used as soon as possible after the event. The earlier the product is taken, the more effective it is likely to be in helping to prevent pregnancy. It is important to note that this product will not terminate an existing pregnancy and does not provide protection against sexually transmitted infections (STIs), including HIV/AIDS.

Regulatory References

1. NIH MedlinePlus guidance

The official regulatory documents establish strict criteria regarding who can and who cannot use Levonorgestrel L.CH. as an emergency contraceptive.

Eligibility Scope: Who Must Not Use

The medication is contraindicated in two absolute scenarios. It must not be used by women with a known or suspected existing pregnancy, as regulatory information confirms the product is ineffective after implantation. Use is also strictly prohibited for individuals with a known hypersensitivity (allergy) to levonorgestrel or any excipient in the formulation.

Age and Physiological Restrictions

Eligibility for the product is based on reproductive status. The medicine is not indicated for use in females who have not yet reached menarche (pre-pubertal age) or for postmenopausal women. Though Levonorgestrel is excreted into breast milk, its use is generally permitted during lactation; however, official regulatory guidance often suggests minimizing infant exposure by avoiding nursing for a specific duration following administration.

Condition-Based Limitations

Certain pre-existing conditions restrict use or require special consideration. The product is not recommended for patients with severe hepatic dysfunction. Additionally, patients with severe malabsorption syndromes (such as Crohn’s disease) may experience reduced effectiveness, as the drug's absorption may be impaired. For both severe hepatic and renal impairment, official formal studies evaluating the drug's effect on disposition were not conducted.

Interactions with other medicines and products

Official regulatory information for Levonorgestrel notes that the effectiveness of the drug can be significantly decreased by co-administration with other substances that accelerate its metabolism. This is primarily classified as a pharmacokinetic interaction where certain medicinal and herbal products induce liver enzymes, specifically Cytochrome P450 3A4 (CYP3A4).

This enzyme induction leads to reduced plasma concentrations of Levonorgestrel, which may compromise its contraceptive effectiveness. The interaction-related reduction in drug levels can persist for up to four weeks after the enzyme-inducing medicine is stopped.

Key Interacting Medicinal Product Categories

Classification	Examples of Affected Classes/Substances
Hepatic Enzyme Inducers (CYP3A4)	Certain medicines for epilepsy (e.g., barbiturates, carbamazepine, phenytoin), tuberculosis (e.g., rifampicin, rifabutin), HIV treatments (e.g., efavirenz, ritonavir), antifungal agents (e.g., griseofulvin).
Herbal Products	St. John’s Wort (Hypericum perforatum).

Interaction-Related Requirements and Constraints

In women who have used a hepatic enzyme inducer in the preceding four weeks, official regulatory guidance indicates that the preferred course is to use a non-hormonal emergency contraceptive method, such as a copper intrauterine device, because it is not affected by these enzyme inducers. If a non-hormonal option is unavailable, the interaction profile may require a procedural modification to the dose of Levonorgestrel to counteract the substantial reduction in drug exposure.

Levonorgestrel L.CH. is a synthetic progestogen that exerts its effects through multiple mechanistic domains. It primarily acts as a progesterone receptor agonist, binding to and activating the nuclear progesterone receptor, which modulates the hormonal feedback loop governing reproductive pathways.

---

Hypothalamic-Pituitary Axis Modulation

This domain involves the drug's action on the central control of reproductive hormones. Levonorgestrel modulates the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This cascade results in altered feedback regulation, influencing the LH surge and subsequent release of a secondary oocyte.

---

Cervical Mucus Viscosity Increase

Levonorgestrel affects the physical consistency of the fluid produced by the cervix. It causes a significant increase in cervical mucus viscosity, which creates a physical change in the environment. This alters mucus rheology, resulting in restricted sperm transport within the cervical canal.

---

Endometrial Regulation Effects

In this domain, the drug induces structural changes in the endometrium (the lining of the uterus). Levonorgestrel modulates endometrial morphology and biochemical characteristics, influencing the receptivity of the uterine tissue.

How to Use Levonorgestrel L.CH. — Official Administration Guidelines

This section outlines the standardized usage principles for Levonorgestrel as emergency contraception.

---

Administration Scope

The approved route for administration is oral, with the medication typically presented as a single tablet formulation. The tablet should be swallowed whole with water and is generally taken without regard to meals.

Standard Dosing and Time-Critical Schedule

Regimen Feature	Standard Instruction
Total Dose	1.5 mg of levonorgestrel.
Frequency Pattern	Single-use course (not for routine, ongoing use).
Time Window	Must be taken as soon as possible after the event.
Maximum Time Limit	Must be administered within 72 hours of the event.

---

Procedural Context and Adjustments

Levonorgestrel may be used at any time during the menstrual cycle. If the patient vomits within three hours of taking the single 1.5 mg dose, a replacement dose should be considered immediately to ensure the full intended amount is absorbed.

Dosing considerations exist for specific populations. For instance, a double dose (3.0 mg total) may be advised for women who are concurrently taking certain medications that are known to speed up the liver's processing of drugs (hepatic enzyme-inducing drugs), provided the copper IUD is not a suitable option.

Connection to the Overall Use Protocol

The official instructions establish Levonorgestrel as a strictly time-sensitive, single-course oral therapy. The protocol is defined by the fixed dose, the oral route, and the critical requirement for administration within a 72-hour period. This administration approach is clinically standardized, with defined steps for managing dose assurance and pharmaceutical interactions.

Levonorgestrel L.CH.: Recent Clinical Evidence

Evidence for Use in Emergency Pregnancy Prevention

Research for Levonorgestrel L.CH. primarily involves Randomized Controlled Trials (RCTs) and Systematic Reviews focused on outcomes related to pregnancy rate following unprotected sexual intercourse or suspected contraceptive failure. These studies examine findings related to its use in women of reproductive age. Research indicates that data show patterns related to the specific time interval between intercourse and drug administration.

---

Analysis of Outcomes Related to Timing

Research has explored various time intervals, analyzing subgroups based on how quickly the medicine was received. Findings describe patterns where reported outcomes varied across different time points of administration. However, research exploring outcomes after administration beyond the currently defined timeframe (e.g., after 72 hours) is limited and does not provide sufficient insight.

---

Research in Specific Groups and Body Weight

Post-pubertal adolescents were included in the populations studied. Separate analyses explored outcomes in subgroups defined by body weight or Body Mass Index (BMI). Findings related to these subgroups were mixed, and certainty remains low regarding outcomes in women with higher body weight. The research contributes to understanding the evidence landscape rather than offering conclusive insights for this specific group.

---

Long-Term Research and Follow-up Duration

Primary clinical trials focused on short-term findings, with follow-up durations limited to tracking the occurrence of the next menstrual period. Consequently, long-term effects are not fully established. There is limited information for long-term outcomes, and few studies have explored the outcomes, including subsequent contraceptive use and related events, when the high-dose regimen is administered multiple times.

---

Key Uncertainties and Areas for Future Research

Key research limitation frames include insufficient data for certain groups and a lack of comparative evidence in some contexts. Primary uncertainties involve the inconsistent outcomes observed for the higher body weight/BMI subgroup, limited evidence for administration beyond 72 hours, and data gaps regarding repeated use. The existing evidence base is extensive for the primary indication but includes these defined research limitations.

Key Studies & References

1. Levonorgestrel: MedlinePlus Drug Information (Authoritative overview of indication and use)
2. WHO Model List of Essential Medicines (Inclusion and regulatory context of levonorgestrel)

Common questions about Levonorgestrel L.CH. (FAQ)

---

Q: How is Levonorgestrel L.CH. different from a standard daily birth control pill?

Levonorgestrel L.CH. is a form of emergency contraception that contains a high concentration of the hormone levonorgestrel. The dose is significantly higher than the daily dose found in routine hormonal birth control pills. According to official information, this product is intended strictly for emergency single-use and is not a substitute for regular contraception.

---

Q: Is Levonorgestrel L.CH. described as effective if taken after a person has already ovulated?

Official information indicates that this medicine works primarily by delaying or inhibiting ovulation (the release of an egg). Therefore, it is generally described as ineffective in preventing pregnancy if the release of the egg has already occurred. Official guidance emphasizes the importance of administration soon after the event.

---

Q: Can a person use Levonorgestrel L.CH. more than once within the same menstrual cycle?

Levonorgestrel is not recommended for routine use, but official health guidance does not prohibit its use more than once within the same menstrual cycle if necessary for separate instances of unprotected sexual intercourse. Official documents maintain that this product is not intended to replace continuous, routine contraception.

---

Q: How might Levonorgestrel L.CH. change the timing or flow of the next expected menstrual period?

Changes to the menstrual cycle are a common side effect described in the official product information. The next period may begin a few days earlier or later than expected. Bleeding patterns may also change, including possible spotting, lighter flow, or heavier flow (menorrhagia) than usual.

---

Q: Is a late or early period after taking Levonorgestrel L.CH. considered within the range of normal expectations?

Regulatory documents note that the next menstrual period may begin a few days earlier or later than the expected date. This change in timing is a common effect of the hormone in the medicine and is generally considered within the range of normal expectations.

---

Q: Does Levonorgestrel L.CH. offer any protection against sexually transmitted infections (STIs)?

No, Levonorgestrel L.CH. is strictly a contraceptive, intended only to reduce the chance of pregnancy. Official labeling is clear that it does not protect against Human Immunodeficiency Virus (HIV/AIDS) or any other sexually transmitted infections (STIs).

---

Q: What information is available regarding the use of Levonorgestrel L.CH. by minors?

Regulatory decisions regarding the levonorgestrel 1.5 mg pill have resulted in its approval for non-prescription (OTC) use for all individuals of childbearing potential, regardless of age, in many regions. This status ensures broad access to the medicine.

---

Q: Is there documented evidence on how Levonorgestrel L.CH. affects a person's mood or emotional state?

Official safety information lists certain psychiatric effects as common adverse reactions. These reported effects can include mood changes, depressed mood, mood swings, decreased libido (sex drive), and nervousness.

---

Q: How long does Levonorgestrel L.CH. typically remain in the body after it is taken?

Pharmacokinetic data in official documents indicate that the active ingredient, levonorgestrel, has a reported half-life of approximately 20 to 24 hours. This data suggests that it takes several days for the drug to be fully eliminated from the body.

---

Q: Does Levonorgestrel L.CH. interact with common over-the-counter pain relievers?

Official drug interaction checkers generally do not show a known interaction between Levonorgestrel L.CH. and common pain relievers like acetaminophen. Patients should refer to the official labeling or consult a healthcare provider for comprehensive interaction information.

---

Q: Can a person take Levonorgestrel L.CH. if they are already using a different hormonal birth control method?

Current regulatory and clinical guidance states there is no concern that taking Levonorgestrel L.CH. concurrently with a systemic hormonal contraceptive decreases the effectiveness of either method.

---

Q: What is the described risk of birth defects if a pregnancy continues after Levonorgestrel L.CH. is taken?

Regulatory statements on fetal risk indicate that Levonorgestrel is not known to cause harmful effects or increase the risk of birth defects if it is inadvertently taken during an early pregnancy that continues. The medicine is not effective at ending an existing pregnancy.

---

Q: Is it possible for side effects from Levonorgestrel L.CH. to feel similar to early signs of pregnancy?

Common adverse effects of Levonorgestrel L.CH., such as nausea, breast tenderness, and fatigue, are also symptoms frequently associated with the early stages of pregnancy, according to official side effect lists.

---

Q: What is the described next step if the menstrual period after taking Levonorgestrel L.CH. is delayed by more than one week?

Official patient instructions state that if the expected menstrual period is delayed by more than 7 days from the anticipated date, this could be a sign of pregnancy. Official patient instructions specify that in this situation, a pregnancy test or consultation with a healthcare professional is indicated.

---

Q: What is the general level of effectiveness described for Levonorgestrel L.CH. in research summaries?

Studies summarized in regulatory documents indicate that the medicine's effectiveness is highest when taken immediately. Efficacy is estimated to reduce the risk of pregnancy by approximately 95% if taken within 24 hours, but this percentage is described as decreasing if treatment is delayed.

---

Q: What is the difference in mechanism of action between Levonorgestrel L.CH. and the emergency copper IUD?

Levonorgestrel L.CH. is a hormonal method that primarily works to delay or prevent ovulation. The copper IUD is a non-hormonal method that affects the viability of sperm and eggs and prevents implantation, and its efficacy is described as the highest among emergency contraceptive options.

---

Q: Do studies suggest that repeated use of Levonorgestrel L.CH. causes more intense side effects?

Current regulatory-supported evidence on repeated use of this medicine does not suggest overall safety concerns. However, specific long-term data regarding the increasing intensity of common side effects are limited. The drug is officially designated for emergency use only and is not intended for use as a primary contraceptive.

---

Q: What is the distinction between Levonorgestrel L.CH. and Ulipristal Acetate as emergency contraceptives?

Both are hormonal emergency contraceptives, but official guidance highlights key differences in their use. Levonorgestrel L.CH. is labeled for use up to 72 hours (3 days) after unprotected sex. Ulipristal Acetate has a defined usage window of up to 120 hours (5 days), a longer period than Levonorgestrel, and its mechanism is described as remaining active closer to the time of ovulation.

Storage and Disposal Requirements

Levonorgestrel tablets must be stored at Controlled Room Temperature, specifically between 20°C to 25°C (68°F to 77°F), with permissible excursions up to 30°C. The product requires protection from light and must be kept in its original package to maintain stability. The tablets should not be used if the blister seal is broken or missing. A mandatory safety instruction is to store the medicine out of the sight and reach of children at all times.

For disposal, any unused or expired Levonorgestrel must be handled in accordance with local requirements. The official documentation specifies that this product or waste material should be discarded following local regulations.